Welcome to our dedicated page for Nu Skin Enter SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Nu Skin Enterprises reported 2025 revenue of $1.485 billion, down from $1.732 billion in 2024 and $1.969 billion in 2023, reflecting pressure on its core direct-selling business. About 85% of 2025 revenue came from Nu Skin-branded operations and 15% from its Rhyz investment arm.
Beauty products generated $568.1 million (38% of sales) and wellness products $689.1 million (46%), with ageLOC lines contributing meaningful portions in both categories. Rhyz businesses produced $223.6 million, while one Rhyz unit, Mavely, was sold after contributing $69.6 million to 2024 revenue.
Customer, paid affiliate and sales leader counts declined across regions, including Mainland China, where a restrictive and evolving regulatory environment continues to create operational risk. The company highlights extensive global regulatory oversight of direct selling, cosmetics, supplements and devices, including heightened FTC scrutiny of multi-level marketing earnings claims and complex licensing rules in China.
Nu Skin Enterprises reported 2025 revenue of $1.485 billion, down from $1.732 billion in 2024 and $1.969 billion in 2023, reflecting pressure on its core direct-selling business. About 85% of 2025 revenue came from Nu Skin-branded operations and 15% from its Rhyz investment arm.
Beauty products generated $568.1 million (38% of sales) and wellness products $689.1 million (46%), with ageLOC lines contributing meaningful portions in both categories. Rhyz businesses produced $223.6 million, while one Rhyz unit, Mavely, was sold after contributing $69.6 million to 2024 revenue.
Customer, paid affiliate and sales leader counts declined across regions, including Mainland China, where a restrictive and evolving regulatory environment continues to create operational risk. The company highlights extensive global regulatory oversight of direct selling, cosmetics, supplements and devices, including heightened FTC scrutiny of multi-level marketing earnings claims and complex licensing rules in China.
Nu Skin Enterprises executive Justin S. Keisel reported stock awards tied to performance goals. On February 10, 2026, he acquired 2,910 shares of Class A common stock at $0.00 per share, increasing his direct holdings to 93,832 shares.
On the same date, he acquired an additional 34,500 shares at $0.00 per share, bringing his direct ownership to 128,332 shares. Both grants relate to previously awarded restricted stock units that became eligible for vesting after Nu Skin met specified performance criteria from 2024 and 2025 grants.
Nu Skin Enterprises executive Justin S. Keisel reported stock awards tied to performance goals. On February 10, 2026, he acquired 2,910 shares of Class A common stock at $0.00 per share, increasing his direct holdings to 93,832 shares.
On the same date, he acquired an additional 34,500 shares at $0.00 per share, bringing his direct ownership to 128,332 shares. Both grants relate to previously awarded restricted stock units that became eligible for vesting after Nu Skin met specified performance criteria from 2024 and 2025 grants.
Nu Skin Enterprises' Chief Product Officer Steven Keith Hatchett reported stock awards tied to performance-based restricted stock units. On February 10, 2026, performance criteria were met for prior RSU grants, resulting in acquisitions of 8,952 and 43,124 shares of Class A Common Stock at $0.00 per share.
After these awards, Hatchett directly held a total of 219,641 Class A shares. The transactions are coded as grants or other acquisitions rather than open-market purchases.
Nu Skin Enterprises' Chief Product Officer Steven Keith Hatchett reported stock awards tied to performance-based restricted stock units. On February 10, 2026, performance criteria were met for prior RSU grants, resulting in acquisitions of 8,952 and 43,124 shares of Class A Common Stock at $0.00 per share.
After these awards, Hatchett directly held a total of 219,641 Class A shares. The transactions are coded as grants or other acquisitions rather than open-market purchases.
Nu Skin Enterprises EVP and General Counsel Chayce David Clark reported stock awards tied to performance goals being met. On February 10, 2026, he acquired 15,667 Class A shares and another 75,466 Class A shares at $0.00 per share as performance-based restricted stock units became eligible for vesting. Following these awards, he directly holds 315,224 Class A shares.
Nu Skin Enterprises EVP and General Counsel Chayce David Clark reported stock awards tied to performance goals being met. On February 10, 2026, he acquired 15,667 Class A shares and another 75,466 Class A shares at $0.00 per share as performance-based restricted stock units became eligible for vesting. Following these awards, he directly holds 315,224 Class A shares.
Nu Skin Enterprises’ Chief Financial Officer James D. Thomas reported equity awards tied to performance goals being met. On February 10, 2026, he acquired 9,847 Class A common shares at $0.00 when 2024 performance-based restricted stock units became eligible to vest.
On the same date, 2025 performance-based restricted stock units also met their criteria, adding a further 47,436 Class A shares at $0.00. Following these grants, Thomas directly owned 192,723 Class A common shares, reflecting increased alignment with shareholders through stock-based compensation.
Nu Skin Enterprises’ Chief Financial Officer James D. Thomas reported equity awards tied to performance goals being met. On February 10, 2026, he acquired 9,847 Class A common shares at $0.00 when 2024 performance-based restricted stock units became eligible to vest.
On the same date, 2025 performance-based restricted stock units also met their criteria, adding a further 47,436 Class A shares at $0.00. Following these grants, Thomas directly owned 192,723 Class A common shares, reflecting increased alignment with shareholders through stock-based compensation.
Nu Skin Enterprises President and CEO Ryan S. Napierski reported performance-based equity awards in Class A common stock. On February 10, 2026, he acquired 42,970 shares and 206,988 shares at a stated price of $0.00 per share through grants classified as awards or other acquisitions.
The Form 4 shows his directly held Class A common stock rising to 686,403 shares after the first transaction and 893,391 shares after the second. Footnotes explain these awards relate to restricted stock units granted in February 2024 and February 2025, which became eligible for vesting once Nu Skin met specified performance criteria on February 10, 2026.
Nu Skin Enterprises President and CEO Ryan S. Napierski reported performance-based equity awards in Class A common stock. On February 10, 2026, he acquired 42,970 shares and 206,988 shares at a stated price of $0.00 per share through grants classified as awards or other acquisitions.
The Form 4 shows his directly held Class A common stock rising to 686,403 shares after the first transaction and 893,391 shares after the second. Footnotes explain these awards relate to restricted stock units granted in February 2024 and February 2025, which became eligible for vesting once Nu Skin met specified performance criteria on February 10, 2026.
Nu Skin Enterprises reported fourth-quarter and full-year 2025 results within guidance, with profitability improving despite lower sales. 2025 revenue was $1.49 billion, down 14.3% from 2024, while diluted EPS rose to $3.18 (or $1.27 excluding the Mavely gain and other charges) from a loss of $(2.95).
Fourth-quarter revenue was $370.3 million, down 16.9%, but EPS improved to $0.29 from $(0.73) as gross margin expanded and restructuring costs fell. Customers declined 10%, and sales leaders fell 19%. For 2026, the company guides revenue to $1.35–$1.50 billion and EPS of $0.80–$1.20, expecting a return to year-over-year revenue growth by year-end driven by its Prysm iO wellness platform and an anticipated India market launch.
Nu Skin Enterprises reported fourth-quarter and full-year 2025 results within guidance, with profitability improving despite lower sales. 2025 revenue was $1.49 billion, down 14.3% from 2024, while diluted EPS rose to $3.18 (or $1.27 excluding the Mavely gain and other charges) from a loss of $(2.95).
Fourth-quarter revenue was $370.3 million, down 16.9%, but EPS improved to $0.29 from $(0.73) as gross margin expanded and restructuring costs fell. Customers declined 10%, and sales leaders fell 19%. For 2026, the company guides revenue to $1.35–$1.50 billion and EPS of $0.80–$1.20, expecting a return to year-over-year revenue growth by year-end driven by its Prysm iO wellness platform and an anticipated India market launch.
Charles Schwab Investment Management Inc. has reported a beneficial ownership stake in Nu Skin Enterprises, Inc. Class A common stock. The firm holds 2,621,785 shares, representing 5.37% of the class as of the event date 12/31/2025.
Schwab reports sole power to vote and dispose of all 2,621,785 shares, with no shared voting or dispositive power. It certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Nu Skin.
Charles Schwab Investment Management Inc. has reported a beneficial ownership stake in Nu Skin Enterprises, Inc. Class A common stock. The firm holds 2,621,785 shares, representing 5.37% of the class as of the event date 12/31/2025.
Schwab reports sole power to vote and dispose of all 2,621,785 shares, with no shared voting or dispositive power. It certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Nu Skin.
Nu Skin Enterprises executive reports share withholding for taxes
Nu Skin Enterprises, Inc. officer Chayce Clark, who serves as EVP and General Counsel, reported a transaction in the company’s Class A common stock on 12/20/2025. A total of 9,049 shares were disposed of at a price of $10.27 per share, coded as an “F” transaction, which indicates shares were withheld by the company to satisfy tax withholding obligations tied to vesting of previously granted restricted stock units. After this tax-related withholding, Clark beneficially owned 224,091 shares of Nu Skin Class A common stock in direct ownership.
Nu Skin Enterprises director reports small share increase through plan dividend
A Nu Skin Enterprises, Inc. director filed a Form 4 reporting the acquisition of 10 shares of Class A common stock on 12/10/2025 at a price of $10.35 per share. The filing states these shares were acquired through dividend reinvestment under the company’s Deferred Compensation Plan in accordance with the plan’s terms. Following this transaction, the director beneficially owns 42,979 shares, held directly. This is a routine insider ownership update showing plan-based reinvestment rather than an open-market trade.